The California Stem Cell Report
Subscribe
Sign in
Home
sustainability
cirm future
CIRM's $3.9 Billion Priority …
A CIRM Primer -- A to Z
CIRM Sustainability
Leaderboard
About
Latest
Top
Discussions
National Research Funding Turmoil and California's Stem Cell Agency's Sustainability
Comments from the CIRM chair, Vito Imbasciani
1 hr ago
•
David Jensen
1
Share this post
The California Stem Cell Report
National Research Funding Turmoil and California's Stem Cell Agency's Sustainability
Copy link
Facebook
Email
Notes
More
Capricor Says CIRM-Backed Therapy is 'Well Postioned' to Move Forward to Clinical Use
Stock rises in trading Tuesday
Jun 25
•
David Jensen
1
Share this post
The California Stem Cell Report
Capricor Says CIRM-Backed Therapy is 'Well Postioned' to Move Forward to Clinical Use
Copy link
Facebook
Email
Notes
More
California's Half-Billion Dollars for Stem Cell/Gene Therapy Research, Plus a Not-So-Secret Sauce for Greater Impact
CIRM board meeting on Thursday to consider all that along with affordability of possible treatments
Jun 23
•
David Jensen
1
Share this post
The California Stem Cell Report
California's Half-Billion Dollars for Stem Cell/Gene Therapy Research, Plus a Not-So-Secret Sauce for Greater Impact
Copy link
Facebook
Email
Notes
More
Capricor, the FDA and Millions from the State of California
Stock price of the San Diego firm drops 31 percent on Friday
Jun 21
•
David Jensen
2
Share this post
The California Stem Cell Report
Capricor, the FDA and Millions from the State of California
Copy link
Facebook
Email
Notes
More
Waning Financial Enthusiasm for Gene Therapies: National Picture is Bleak, Says Barron's
California multibillion-dollar program scheduled to discuss its research portfolio next week
Jun 19
•
David Jensen
1
Share this post
The California Stem Cell Report
Waning Financial Enthusiasm for Gene Therapies: National Picture is Bleak, Says Barron's
Copy link
Facebook
Email
Notes
More
Sarepta's Stock Sinks Sharply Following News of Second Death Involving Genetic Therapy
$3.2 million treatment, Duchenne disorder and 'regulatory flexibility' involved
Jun 16
•
David Jensen
1
Share this post
The California Stem Cell Report
Sarepta's Stock Sinks Sharply Following News of Second Death Involving Genetic Therapy
Copy link
Facebook
Email
Notes
More
Second Death in Gene Therapy Trial for a Rare Muscle Degenerative Disorder
'Regulatory flexibility' issues surrounding the case could affect development of other gene therapies, including those financed by California taxpayers.
Jun 16
•
David Jensen
1
Share this post
The California Stem Cell Report
Second Death in Gene Therapy Trial for a Rare Muscle Degenerative Disorder
Copy link
Facebook
Email
Notes
More
Who are the Big Winners of California's Billions for Stem Cell and Gene Therapy Research?
The money flows from San Diego to Sacramento.
Jun 12
•
David Jensen
1
Share this post
The California Stem Cell Report
Who are the Big Winners of California's Billions for Stem Cell and Gene Therapy Research?
Copy link
Facebook
Email
Notes
More
Easing of Regulation of Unproven Stem Cell Therapies Looming; RFK Jr. Discloses His Treatment
Robert F.
Jun 9
•
David Jensen
1
Share this post
The California Stem Cell Report
Easing of Regulation of Unproven Stem Cell Therapies Looming; RFK Jr. Discloses His Treatment
Copy link
Facebook
Email
Notes
More
California's Stem Cell/Gene Therapy Budget to Hit All-Time High of More than $500 Million
Spending plan boosted to help deal with Trump's research machinations
Jun 4
•
David Jensen
Share this post
The California Stem Cell Report
California's Stem Cell/Gene Therapy Budget to Hit All-Time High of More than $500 Million
Copy link
Facebook
Email
Notes
More
California Gene Therapy Program Expresses Condolences Following Death of Patient in Clinical Trial
CIRM backed the research with $5.8 million
Jun 2
•
David Jensen
Share this post
The California Stem Cell Report
California Gene Therapy Program Expresses Condolences Following Death of Patient in Clinical Trial
Copy link
Facebook
Email
Notes
More
May 2025
Death in Clinical Trial Supported With $5.8 Million From California Stem Cell and Gene Therapy Agency
Rocket Pharma says it will seek to move forward with the treatment; company's stock plummets
May 30
•
David Jensen
Share this post
The California Stem Cell Report
Death in Clinical Trial Supported With $5.8 Million From California Stem Cell and Gene Therapy Agency
Copy link
Facebook
Email
Notes
More
Share
Copy link
Facebook
Email
Notes
More
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts